Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price Target & Predictions
CYCC Stock Forecast
Cyclacel Pharmaceuticals stock forecast is as follows: an average price target of $1.00 (represents a 215.06% upside from CYCC’s last price of $0.32) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CYCC Price Target
The average price target for Cyclacel Pharmaceuticals (CYCC) is $1.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $1.00 to $1.00. This represents a potential 215.06% upside from CYCC's last price of $0.32.
CYCC Analyst Ratings
According to 1 Wall Street analysts, Cyclacel Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CYCC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cyclacel Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 23, 2024 | Jonathan Aschoff | Roth Capital | $1.00 | $1.14 | -12.28% | 215.06% |
The latest Cyclacel Pharmaceuticals stock forecast, released on Oct 23, 2024 by Jonathan Aschoff from Roth Capital, set a price target of $1.00, which represents a -12.28% decrease from the stock price at the time of the forecast ($1.14), and a 215.06% increase from CYCC last price ($0.32).
Cyclacel Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $1.00 | $1.00 |
| Last Closing Price | $0.32 | $0.32 | $0.32 |
| Upside/Downside | -100.00% | 215.06% | 215.06% |
In the current month, the average price target of Cyclacel Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cyclacel Pharmaceuticals's last price of $0.32. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 07, 2023 | Oppenheimer | Outperform | Outperform | Hold |
Cyclacel Pharmaceuticals's last stock rating was published by Oppenheimer on Mar 07, 2023. The company gave CYCC a "Outperform" rating, the same as its previous rate.
Cyclacel Pharmaceuticals Financial Forecast
Cyclacel Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 16 | Mar 15 | Mar 14 | Jun 13 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $205.00K | $512.00K | $396.00K | $264.00K | $161.00K | $192.00K | $271.00K | $228.00K | - | - | - | - | - |
| Avg Forecast | $25.00K | $25.00K | $25.00K | $25.00K | $10.00K | $10.00K | $30.00K | $229.53K | $671.05K | $421.33K | $1.04M | $214.00 | $161.50K | $225.00K | $271.40K | $199.35K | $76.54K | $46.41K | $60.00K | $31.90K |
| High Forecast | $25.00K | $25.00K | $25.00K | $25.00K | $10.00K | $10.00K | $30.00K | $275.44K | $805.26K | $505.60K | $1.25M | $256.00 | $193.80K | $270.00K | $325.68K | $239.22K | $91.85K | $55.69K | $72.00K | $38.28K |
| Low Forecast | $25.00K | $25.00K | $25.00K | $25.00K | $10.00K | $10.00K | $30.00K | $183.63K | $536.84K | $337.06K | $832.00K | $170.00 | $129.20K | $180.00K | $217.12K | $159.48K | $61.23K | $37.13K | $48.00K | $25.52K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 18 | 17 | 9 | 15 | 13 | 8 | 8 | 16 | 8 | 7 | 18 | 18 |
| Surprise % | - | - | - | - | - | - | - | 0.89% | 0.76% | 0.94% | 0.25% | 752.34% | 1.19% | 1.20% | 0.84% | - | - | - | - | - |
Cyclacel Pharmaceuticals's average Quarter revenue forecast for Jun 24 based on 1 analysts is $30.00K, with a low forecast of $30.00K, and a high forecast of $30.00K. CYCC's average Quarter revenue forecast represents a -85.37% decrease compared to the company's last Quarter revenue of $205.00K (Sep 16).
Cyclacel Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 16 | Mar 15 | Mar 14 | Jun 13 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 18 | 17 | 9 | 15 | 13 | 8 | 8 | 16 | 8 | 7 | 18 | 18 |
| EBITDA | - | - | - | - | - | - | - | $-3.37M | $-5.62M | $-5.42M | $1.27M | $-3.11M | $-4.69M | $-5.09M | $-5.13M | - | - | - | - | - |
| Avg Forecast | $15.00K | $15.00K | $15.00K | $15.00K | $6.00K | $6.00K | $18.00K | $-3.65M | $-6.97M | $-5.69M | $624.00K | $-3.88M | $-3.86M | $-4.07M | $-5.91M | $-7.63M | $-7.03M | $-14.01M | $-7.13M | $-14.26M |
| High Forecast | $15.00K | $15.00K | $15.00K | $15.00K | $6.00K | $6.00K | $18.00K | $-2.92M | $-5.58M | $-4.55M | $748.80K | $-3.11M | $-3.09M | $-3.26M | $-4.73M | $-6.10M | $-5.63M | $-11.20M | $-5.70M | $-11.41M |
| Low Forecast | $15.00K | $15.00K | $15.00K | $15.00K | $6.00K | $6.00K | $18.00K | $-4.38M | $-8.37M | $-6.83M | $499.20K | $-4.66M | $-4.64M | $-4.89M | $-7.09M | $-9.16M | $-8.44M | $-16.81M | $-8.55M | $-17.11M |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 0.81% | 0.95% | 2.04% | 0.80% | 1.21% | 1.25% | 0.87% | - | - | - | - | - |
17 analysts predict CYCC's average Quarter EBITDA for Mar 14 to be $-5.69M, with a high of $-4.55M and a low of $-6.83M. This is -547.26% lower than Cyclacel Pharmaceuticals's previous annual EBITDA (Jun 13) of $1.27M.
Cyclacel Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 16 | Mar 15 | Mar 14 | Jun 13 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 18 | 17 | 9 | 15 | 13 | 8 | 8 | 16 | 8 | 7 | 18 | 18 |
| Net Income | - | - | - | - | - | - | - | $-2.95M | $-4.91M | $-4.87M | $1.49M | $-2.96M | $-4.59M | $-5.11M | $-5.06M | - | - | - | - | - |
| Avg Forecast | $-645.66K | $-645.66K | $-645.66K | $-624.14K | $-624.14K | $-1.16M | $-3.09M | $-3.20M | $-6.09M | $-5.12M | $3.07M | $-3.69M | $-3.78M | $-4.09M | $-5.84M | $-6.86M | $-6.59M | $-13.98M | $-7.58M | $-48.61M |
| High Forecast | $-645.66K | $-645.66K | $-645.66K | $-624.14K | $-624.14K | $-1.16M | $-3.09M | $-2.56M | $-4.87M | $-4.09M | $3.68M | $-2.96M | $-3.02M | $-3.27M | $-4.67M | $-5.49M | $-5.27M | $-11.19M | $-6.06M | $-38.89M |
| Low Forecast | $-645.66K | $-645.66K | $-645.66K | $-624.14K | $-624.14K | $-1.16M | $-3.09M | $-3.84M | $-7.31M | $-6.14M | $2.46M | $-4.43M | $-4.53M | $-4.91M | $-7.00M | $-8.23M | $-7.90M | $-16.78M | $-9.09M | $-58.33M |
| Surprise % | - | - | - | - | - | - | - | 0.92% | 0.81% | 0.95% | 0.49% | 0.80% | 1.21% | 1.25% | 0.87% | - | - | - | - | - |
Cyclacel Pharmaceuticals's average Quarter net income forecast for Mar 14 is $-5.12M, with a range of $-6.14M to $-4.09M. CYCC's average Quarter net income forecast represents a -442.86% decrease compared to the company's last Quarter net income of $1.49M (Jun 13).
Cyclacel Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 16 | Mar 15 | Mar 14 | Jun 13 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 18 | 17 | 9 | 15 | 13 | 8 | 8 | 16 | 8 | 7 | 18 | 18 |
| SG&A | - | - | - | - | - | - | - | $1.27M | $1.47M | $1.46M | $1.79M | $2.00M | $1.81M | $2.40M | $2.23M | - | - | - | - | - |
| Avg Forecast | $99.98K | $99.98K | $99.98K | $99.98K | $39.99K | $39.99K | $119.97K | $917.92K | $2.68M | $1.68M | $4.16M | $855.00 | $645.85K | $899.78K | $1.09M | $797.23K | $306.10K | $185.59K | $239.94K | $127.57K |
| High Forecast | $99.98K | $99.98K | $99.98K | $99.98K | $39.99K | $39.99K | $119.97K | $1.10M | $3.22M | $2.02M | $4.99M | $1.02K | $775.01K | $1.08M | $1.30M | $956.66K | $367.31K | $222.70K | $287.93K | $153.09K |
| Low Forecast | $99.98K | $99.98K | $99.98K | $99.98K | $39.99K | $39.99K | $119.97K | $734.33K | $2.15M | $1.35M | $3.33M | $679.00 | $516.68K | $719.83K | $868.27K | $637.78K | $244.87K | $148.47K | $191.95K | $102.06K |
| Surprise % | - | - | - | - | - | - | - | 1.39% | 0.55% | 0.87% | 0.43% | 2334.50% | 2.80% | 2.67% | 2.05% | - | - | - | - | - |
Cyclacel Pharmaceuticals's average Quarter SG&A projection for Jun 24 is $119.97K, based on 1 Wall Street analysts, with a range of $119.97K to $119.97K. The forecast indicates a -90.58% fall compared to CYCC last annual SG&A of $1.27M (Sep 16).
Cyclacel Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 16 | Mar 15 | Mar 14 | Jun 13 | Mar 12 | Mar 11 | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 18 | 17 | 9 | 15 | 13 | 8 | 8 | 16 | 8 | 7 | 18 | 18 |
| EPS | - | - | - | - | - | - | - | $-17.20 | $-45.60 | $-60.00 | $24.00 | $-100.80 | $-168.00 | $-302.40 | $-420.00 | - | - | - | - | - |
| Avg Forecast | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.29 | $-0.54 | $-1.44 | $-1.02 | $-3.72 | $-66.40 | $-172.80 | $-168.00 | $-117.60 | $-201.60 | $-571.20 | $-632.80 | $-935.20 | $-1.16K | $-6.72K | $-14.52K |
| High Forecast | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.29 | $-0.54 | $-1.44 | $-0.82 | $-2.98 | $-53.12 | $-138.24 | $-134.40 | $-94.08 | $-161.28 | $-456.96 | $-506.24 | $-748.16 | $-927.36 | $-5.38K | $-11.61K |
| Low Forecast | $-0.30 | $-0.30 | $-0.30 | $-0.29 | $-0.29 | $-0.54 | $-1.44 | $-1.22 | $-4.46 | $-79.68 | $-207.36 | $-201.60 | $-141.12 | $-241.92 | $-685.44 | $-759.36 | $-1.12K | $-1.39K | $-8.06K | $-17.42K |
| Surprise % | - | - | - | - | - | - | - | 16.86% | 12.26% | 0.90% | -0.14% | 0.60% | 1.43% | 1.50% | 0.74% | - | - | - | - | - |
According to 17 Wall Street analysts, Cyclacel Pharmaceuticals's projected average Quarter EPS for Mar 14 is $-66.40, with a low estimate of $-79.68 and a high estimate of $-53.12. This represents a -376.67% decrease compared to CYCC previous annual EPS of $24.00 (Jun 13).
Cyclacel Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $1.00 | $30.00 | 2900.00% | |
| SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
| OVID | Ovid Therapeutics | $1.06 | $3.00 | 183.02% | Buy |
| CYCC | Cyclacel Pharmaceuticals | $0.37 | $1.00 | 170.27% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |